A cardiac PET scan (positron emission tomography) is a highly accurate, non-invasive nuclear imaging test that uses a radioactive tracer to produce detailed images of how blood flows through the heart muscle and how well the heart is functioning at a cellular level.
A cardiac PET scan is a highly accurate nuclear medicine imaging test used to evaluate the heart’s myocardial perfusion, viability, and metabolism.
It is considered the gold standard for assessing myocardial blood flow and detecting coronary artery disease (CAD).
It is often combined with a CT scan (PET/CT) to provide both functional and anatomical information.
A cardiac PET scan is considered the standard for assessing blood flow and tissue viability and may be used when other tests do not provide enough information.
Uses:
Diagnose coronary artery disease (CAD): It can detect areas of poor blood flow or blockages that may be missed by other tests.
Myocardial Perfusion Imaging (MPI) can detects areas of reduced blood flow (ischemia) or scar (infarction)
It is superior to SPECT/traditional nuclear stress test, in accuracy, especially in obese patients or women
It can assess heart damage, distinguishing between healthy, damaged, and scarred heart tissue, often a result of a past heart attack.
Helps determine if procedures like angioplasty, stenting, or coronary artery bypass surgery would be beneficial.
Monitors treatment effectiveness: Multiple scans over time can show how well ongoing treatments for heart conditions are working.
Diagnose specific cardiac diseases: cardiac sarcoidosis and certain types of heart infections.
Evaluate high-risk patients: It is especially useful for patients who have a high BMI, have breast implants, or have excess chest wall tissue, as these factors can make other imaging tests less accurate.
The procedure usually takes one to three hours.
A small amount of radioactive tracer is injected through the IV and images of the heart are taken at rest.
Stress Scan: Medication is administered through the IV to chemically induce a stress on the heart, mimicking the effect of exercise (a pharmacologic stress test.
Another dose of the tracer is injected, and a second set of images is taken to compare blood flow under stress versus at rest.
The scanner detects signals from the tracer, and a computer converts these signals into detailed 3D pictures of the heart.
Myocardial Blood Flow Quantification
Cardiac PET measures blood flow in mL/min/g of tissue, not just relative uptake.
Detects balanced ischemia with three-vessel disease that SPECT often misses.
Can Identify microvascular dysfunction
Myocardial Viability Assessment using 18F-FDG PET to detect hibernating viable but dysfunctional myocardium
Can Help decide if revascularization (bypass/stent) will improve heart function.
Cardiac Sarcoidosis & Inflammatory Cardiomyopathies 18F-FDG PET detects active inflammation in the heart: cardiac sarcoidosis, and inflammatory cardiomyopathies.
Advantages Over SPECT Higher spatial and contrast resolution Lower radiation dose, especially with Rb-82 or Flurpiridaz Shorter protocol (15–30 min vs 3–4 hours for SPECT) Absolute flow quantification Better diagnostic accuracy (sensitivity/specificity >90–95%)
Typical Protocol (Rb-82 PET) 1 Rest perfusion scan (Rb-82 injection at rest) 2 Stress perfusion scan ◦ Pharmacologic stress (regadenoson, adenosine, or dipyridamole) ◦ Rb-82 injected at peak stress 3 Gated images → assess left ventricular function (ejection fraction) 4 Optional: CT attenuation correction and calcium scoring Radiation Exposure • Rb-82 PET: ~1–3 mSv (very low) • N-13 Ammonia: ~2–4 mSv • F-18 FDG viability: ~7–10 mSv . SPECT Tc-99m is ~8–12 mSv, background yearly radiation ~3 mSv)
Benefits • Obese patients (BMI >35) • Women (less breast artifact) • Suspected multi-vessel or left main disease • Intermediate-risk patients with equivocal SPECT • Pre-transplant evaluation • Known CAD with unclear symptoms Limitations Higher cost than SPECT Limited availability
Rb-82 requires an on-site generator.
In summary, cardiac PET is the most accurate noninvasive test for coronary artery disease and myocardial viability, especially valuable in complex or high-risk patients. It is increasingly recommended in guidelines over SPECT when available.